Several preclinical studies were performed in orthotopic glioma mouse models with CD8+ CAR-T cells that targeted IL-13Rα2, including a CAR construct that was optimized with a 4-1BB co-stimulatory domain [28,29,30,31,32]. This evidence concerns the gene IL13RA2 and central nervous system cancer.